Medical Editor: John P. Cunha, DO, FACOEP
What Is Fludeoxyglucose F 18?
Fludeoxyglucose F 18 Injection (fdg) is a positron emitting radiopharmaceutical used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). Fludeoxyglucose F 18 Injection is used to assist assessment of cancer, coronary artery disease, or epileptic seizures.
What Are Side Effects of Fludeoxyglucose F 18?Side effects from Fludeoxyglucose F 18 Injection are uncommon. Infrequent side effects of Fludeoxyglucose F 18 Injection include allergic reactions, itching, rash, and water retention.
Dosage for Fludeoxyglucose F 18?
The recommended dose of Fludeoxyglucose F 18 Injection (fdg) for an adult (70 kg) is 185-370 MBq (5-10 mCi), as an intravenous injection for studies of malignancy, cardiology and epilepsy. Use in patients with diabetes mellitus or hyperglycemia has not been well studied. It is recommended that patients be normoglycemic when undergoing PET imaging with Fludeoxyglucose F 18 Injection (fdg).
What Drugs, Substances, or Supplements Interact with Fludeoxyglucose F 18?
Fludeoxyglucose F 18 During Pregnancy and Breastfeeding
Other drugs may interact with Fludeoxyglucose. Tell your doctor all medications you use. Talk to your doctor about taking Fludeoxyglucose if you are pregnant or breastfeeding.
Our Fludeoxyglucose F 18 Injection (fdg) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The [18F]FDG safety data base was evaluated for 374 patients. Of these, 245 were male and 105 were female. For 24 patients, gender was not specified. The mean age was 47.8 years (range under 2 to over 65 years). Eighteen patients were between the age of 0 and 2 years; 42 patients were between the ages of 2 and 21 years old; 213 patients were between 21 and 65 years old and 98 patients were older than 65 years and the ages of 3 male patients were not specified. A racial distribution is not available. In this database, adverse drug reactions that required medical intervention were not reported.
In a small, 42 patient subset of the 374 patients studied, 4 patients had transient hypotension, 6 had hypo- or hyperglycemia and 3 had transient increases in alkaline phosphatase.
Read the entire FDA prescribing information for Fludeoxyglucose (FDG)
© Fludeoxyglucose Patient Information is supplied by Cerner Multum, Inc. and Fludeoxyglucose Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.